Michael R. Pavia

Azevan Pharmaceuticals, Inc. develops novel therapeutics to treat disorders of stress, mood, and behavior. Its first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and major depression. The company was founded by Craig F. Ferris and Neal Gordon Simon in 1999 and is headquartered in Bethlehem.

Segterra, Inc. engages in the development and marketing of a health and fitness analytics platform. It offers InsideTracker, which tracks and analyzes key biochemical and physiological markers and applies algorithms and scientific databases to determine personalized optimal zones for each marker. The company was founded by Richard Arnstein, Gil Blander, Christina Reich and David Lester in 2009 and is headquartered in Cambrdige, MA.

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

The North Carolina Biotechnology Center provides research and education grants. Its services include financing, technology assessment, business planning, and marketing strategies implementation. The company was founded in 1984 and is headquartered in Research Triangle Park, NC.

Luca Technologies, Inc. operates as a clean energy company. Its proprietary technology stimulates native microorganisms that reside in subsurface hydrocarbon deposits, such as coal, oil and organic-rich shales to accelerate the bioconversion of such resources into methane, the principal component of natural gas, which the company produces and sells using existing infrastructure. The company was founded by Eric Szaloczi, R. Verlin Dannar, Jeffrey L. Weber, Robert S. Pfeiffer, Michael P. Batzer, Christie L. Haas, Roland P. DeBruyn, and Allan F. Wise in April 2003 and is headquartered in Golden, CO.

Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston.

Selventa, Inc. develops new approaches for the understanding and treatment of diseases. It focuses on elucidating the complexity of biology for the development of safe and effective therapeutics and molecular diagnostics. The company was founded in 2002 by Keith O. Elliston and Noubar B. Afeyan and is headquartered in Cambridge, MA.